BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 36107387)

  • 1. CPLX2 Regulates Ferroptosis and Apoptosis Through NRF2 Pathway in Human Hepatocellular Carcinoma Cells.
    Li H; Zhao J; Zhong XL; Xu PY; Du LJ; Fang P; Tan LJ; Li MJ; Zhang CF; Cao TS
    Appl Biochem Biotechnol; 2023 Jan; 195(1):597-609. PubMed ID: 36107387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of MCF2L Promoted the Ferroptosis of Hepatocellular Carcinoma Cells through PI3K/mTOR Pathway in a RhoA/Rac1 Dependent Manner.
    Huang SC; Chen YM; Hu YY; Shi YJ; Xiao QW; Li Z; Kang JL; Zhou Q; Shen G; Jia HY
    Dis Markers; 2022; 2022():6138941. PubMed ID: 36330204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis.
    Yang R; Gao W; Wang Z; Jian H; Peng L; Yu X; Xue P; Peng W; Li K; Zeng P
    Phytomedicine; 2024 Jan; 122():155135. PubMed ID: 37856990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
    Yang C; Lu T; Liu M; Yuan X; Li D; Zhang J; Zhou L; Xu M
    Phytomedicine; 2023 Mar; 111():154668. PubMed ID: 36657316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2.
    Elkateb AS; Nofal S; Ali SA; Atya HB
    Inflammation; 2023 Aug; 46(4):1493-1511. PubMed ID: 37171695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.
    Lu Z; Yang H; Shao Y; Sun W; Jiang Y; Li J
    Biochem Biophys Res Commun; 2022 Oct; 627():103-110. PubMed ID: 36030651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis.
    Zhang Y; Tan Y; Liu S; Yin H; Duan J; Fan L; Zhao X; Jiang B
    Toxicol Mech Methods; 2023 Jan; 33(1):47-55. PubMed ID: 35592903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
    Wang Q; Bin C; Xue Q; Gao Q; Huang A; Wang K; Tang N
    Cell Death Dis; 2021 Apr; 12(5):426. PubMed ID: 33931597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma.
    Iseda N; Itoh S; Toshida K; Tomiyama T; Morinaga A; Shimokawa M; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Yoshizumi T; Mori M
    Cancer Sci; 2022 Jul; 113(7):2272-2287. PubMed ID: 35466502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
    Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y
    J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CISD2 Promotes Resistance to Sorafenib-Induced Ferroptosis by Regulating Autophagy in Hepatocellular Carcinoma.
    Li B; Wei S; Yang L; Peng X; Ma Y; Wu B; Fan Q; Yang S; Li X; Jin H; Tang S; Huang M; Li H; Liu J
    Front Oncol; 2021; 11():657723. PubMed ID: 34485112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocadherin 20 promotes ferroptosis by suppressing the expression of Sirtuin 1 and promoting the acetylation of nuclear factor erythroid 2-related factor 2 in hepatocellular carcinoma.
    Jun L; Chen W; Han L; Yanmin L; Qinglei Z; Pengfei Z
    Int J Biochem Cell Biol; 2023 Mar; 156():106363. PubMed ID: 36641129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.
    Xu FL; Wu XH; Chen C; Wang K; Huang LY; Xia J; Liu Y; Shan XF; Tang N
    Cell Death Dis; 2023 Jan; 14(1):22. PubMed ID: 36635256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
    Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
    Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma.
    Leung HW; Lau EYT; Leung CON; Lei MML; Mok EHK; Ma VWS; Cho WCS; Ng IOL; Yun JP; Cai SH; Yu HJ; Ma S; Lee TKW
    Cancer Lett; 2020 Apr; 476():48-56. PubMed ID: 32061952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.
    Sun X; Ou Z; Chen R; Niu X; Chen D; Kang R; Tang D
    Hepatology; 2016 Jan; 63(1):173-84. PubMed ID: 26403645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Metformin and Sorafenib Induces Ferroptosis of Hepatocellular Carcinoma Through p62-Keap1-Nrf2 Pathway.
    Tang K; Chen Q; Liu Y; Wang L; Lu W
    J Cancer; 2022; 13(11):3234-3243. PubMed ID: 36118519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis.
    Ren X; Li Y; Zhou Y; Hu W; Yang C; Jing Q; Zhou C; Wang X; Hu J; Wang L; Yang J; Wang H; Xu H; Li H; Tong X; Wang Y; Du J
    Redox Biol; 2021 Oct; 46():102122. PubMed ID: 34482117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TEA Domain Transcription Factor 1 Inhibits Ferroptosis and Sorafenib Sensitivity of Hepatocellular Carcinoma Cells.
    Li H; Lan H; Zhang M; Zhao F; An N; Yi C
    Dig Dis Sci; 2023 Jul; 68(7):3070-3082. PubMed ID: 36680650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation.
    Sun J; Zhou C; Zhao Y; Zhang X; Chen W; Zhou Q; Hu B; Gao D; Raatz L; Wang Z; Nelson PJ; Jiang Y; Ren N; Bruns CJ; Zhou H
    Redox Biol; 2021 May; 41():101942. PubMed ID: 33770521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.